Trump announces trade deal with EU following months of negotiations
WESTBROOK, Maine - IDEXX Laboratories, Inc. (NASDAQ:IDXX) reported fourth quarter earnings and revenue that exceeded analyst expectations, sending shares up 0.70% in early trading on Monday.
The pet healthcare company posted adjusted earnings per share of $2.62, beating the consensus estimate of $2.39. Revenue came in at $954.28 million, surpassing expectations of $933.38 million.
IDEXX’s fourth quarter revenue grew 6% year-over-year on both a reported and organic basis. The growth was driven by a 6% increase in Companion Animal Group revenue and a 7% organic rise in CAG Diagnostics recurring revenue.
"IDEXX had a solid finish to 2024, supported by continued high levels of execution by IDEXX teams globally," said Jay Mazelsky, President and CEO. He highlighted the company’s recent launch of new products like the IDEXX inVue Dx Cellular Analyzer.
For the full year 2025, IDEXX forecasts revenue between $4.05 billion and $4.17 billion, representing growth of 4-7% as reported and 6-9% on an organic basis. The company expects adjusted EPS of $11.74 to $12.24.
The guidance range for CAG Diagnostics recurring revenue growth reflects goals for sustained benefits from execution drivers, supporting continued solid volume gains, and an estimated 4-4.5% full year benefit from net price improvement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.